Multiple phase II trials are underway for evaluating the PARP depressants in CCA, including monotherapy(NCT04042831, NCT03207347, NCT03212274) and combination with PD-1/PD-L1 inhibitors(NCT04895046, NCT04306367) or temozolomide(NCT04796454), demonstrating considerable efficacy. This evidence concerns the gene CD274 and cholangiocarcinoma.